Teacher Retirement System of Texas Has $153,000 Stock Position in Altimmune, Inc. (NASDAQ:ALT)

Teacher Retirement System of Texas increased its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 19.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 21,205 shares of the company’s stock after buying an additional 3,423 shares during the quarter. Teacher Retirement System of Texas’ holdings in Altimmune were worth $153,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in Altimmune in the 3rd quarter valued at approximately $674,000. Barclays PLC raised its stake in Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after buying an additional 75,064 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the period. FMR LLC grew its stake in Altimmune by 546.8% during the third quarter. FMR LLC now owns 51,060 shares of the company’s stock worth $314,000 after purchasing an additional 43,166 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Altimmune by 27.5% during the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock worth $1,211,000 after acquiring an additional 42,553 shares in the last quarter. Institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Tuesday, March 18th. Finally, Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.83.

Altimmune Stock Performance

NASDAQ:ALT opened at $4.78 on Thursday. Altimmune, Inc. has a 52 week low of $4.65 and a 52 week high of $11.16. The firm has a 50-day moving average price of $6.12 and a two-hundred day moving average price of $7.00. The firm has a market cap of $368.13 million, a price-to-earnings ratio of -3.08 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, sell-side analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Insider Activity

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were acquired at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.10% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.